טוען...
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to obtain optimal responses ac...
שמור ב:
| הוצא לאור ב: | Mol Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817805/ https://ncbi.nlm.nih.gov/pubmed/29455672 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0805-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|